Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies

Wagle, Susbin Raj; Kovačević, Božica; Walker, Daniel P.; Ionescu, Corina Mihaela; Shah, Umar; Stojanović, Goran; Kojić, Sanja; Mooranian, Armin; Al‐Salami, Hani

doi:10.1080/17425247.2020.1789587

Cited by 43 publications

(28 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, CDCA microcapsules were prepared using our Ionic Gelation Vibrational Jet Flow technology via ionotropic gelation processed using main encapsulating parameters, based on Büchi customized technology (Büchi, Switzerland) [ 30 , 40 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. A multitude of topographic assessments were conducted, with microscopy imaging, surface spectral analyses and CDCA surface distribution assessments, scanning electron imaging, energy dispersive X-ray spectroscopy, and confocal image measurements; all of which were carried out on three randomly selected batches at the John De Laeter center, as well as at the Curtin Health Innovation Research Institute (Bentley, WA, Australia).…”

Section: Methodsmentioning

confidence: 99%

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study

Mooranian

Ionescu

Wagle

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Introduction. Primary bile acids (PBAs) are produced and released into human gut as a result of cholesterol catabolism in the liver. A predominant PBA is chenodeoxycholic acid (CDCA), which in a recent study in our laboratory, showed significant excipient-stabilizing effects on microcapsules carrying insulinoma β-cells, in vitro, resulting in improved cell functions and insulin release, in the hyperglycemic state. Hence, this study aimed to investigate the applications of CDCA in bio-encapsulation and transplantation of primary healthy viable islets, preclinically, in type 1 diabetes. Methods. Healthy islets were harvested from balb/c mice, encapsulated in CDCA microcapsules, and transplanted into the epididymal tissues of 6 syngeneic diabetic mice, post diabetes confirmation. Pre-transplantation, the microcapsules’ morphology, size, CDCA-deep layer distribution, and physical features such as swelling ratio and mechanical strength were analyzed. Post-transplantation, animals’ weight, bile acids’, and proinflammatory biomarkers’ concentrations were analyzed. The control group was diabetic mice that were transplanted encapsulated islets (without PBA). Results and Conclusion. Islet encapsulation by PBA microcapsules did not compromise the microcapsules’ morphology or features. Furthermore, the PBA-graft performed better in terms of glycemic control and resulted in modulation of the bile acid profile in the brain. This is suggestive that the improved glycemic control was mediated via brain-related effects. However, the improvement in graft insulin delivery and glycemic control was short-term.

show abstract

Section: Methodsmentioning

confidence: 99%

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study

Mooranian

Ionescu

Wagle

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…The MVSA solution and drug formulations were mixed at the same speed at room temperature. The formulations were prepared according to a protocol developed in-house and published previously [ 17 , 18 ]. The aforementioned protocol has been optimised through a series of experiments for rheology, fluid dynamics and colloidal dispersion electrokinetic (Zeta potentials) to ensure total emulsification of the drug content into the MVSA solution.…”

Section: Methodsmentioning

confidence: 99%

Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Cannabidiol (CBD) confers therapeutic effects in some neurological disorders via modulation of inflammatory, oxidative and cell-signalling pathways. However, CBD is lipophilic and highly photooxidative with low oral bioavailability in plasma and brain. In this study, we aimed to design and test a CBD microencapsulation method as a drug delivery strategy to improve the absorption of CBD. Additionally, we evaluated the brain uptake of CBD capsules when administered alongside capsules containing a permeation-modifying bile acid, deoxycholic acid (DCA). Methods Microcapsules containing either CBD or DCA were formed using the ionic gelation method with 1.5% sodium alginate formulations and 100 mM calcium chloride. C57BL/6J wild type mice randomly assigned to three treatment groups (3–4 mice per group) were administered CBD in the following preparations: 1) CBD capsules, 2) CBD capsules + DCA capsules and 3) naked CBD oil (control). To assess the short-term bioavailability of CBD, plasma and brain samples were collected at 0.3, 1 and 3 hours post administration and CBD levels were analysed with liquid chromatography mass spectrometer. Results We produced spherical capsules at 400 ± 50 μm in size. The CBD capsules were calculated to have a drug loading of 2% and an encapsulation efficiency of 23%. Mice that received CBD capsules + DCA capsules showed a 40% and 47% increase in CBD plasma concentration compared to mice on CBD capsules and naked CBD oil, respectively. Furthermore, the CBD capsules + DCA capsules group showed a 48% and 25% increase in CBD brain concentration compared to mice on CBD capsules and naked CBD oil, respectively. In mice treated with CBD capsules + DCA capsules, the brain CBD concentration peaked at 0.3 hours with a 300% increased availability compared to CBD capsules and naked CBD oil groups, which peaked at 1 hour after administration. Conclusions The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain.

show abstract

“…For analyses of IL-1β, IL-6, IL-12, IL-17, IFN-γ, and TNF-α in plasma, cytokine bead array (CBA) kits were acquired from BD Biosciences (San Jose, CA, USA) and were used as per the manufacturer’s instructions and as per our well-established methods [ 35 , 36 , 37 ]. For each sample, sample processing and mixing involved protein extraction, solubilisation, reagent dilution, and precipitation, and the concentrations of the cytokines were determined and analysed by Attune Acoustic Focusing flow cytometry (Carlsbad Life Technologies, Carlsbad, CA, USA) using refined methods described in depth in our previously published papers [ 34 , 35 , 36 ].…”

Section: Methodsmentioning

confidence: 99%

Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction. A major obstacle in islet transplantation and graft survival pre and post transplantation is islet apoptosis due to mainly inflammatory bio molecules released during islet harvesting and post graft transplantation and hence, subsequent graft fibrosis and failure. This study aimed to investigate if incorporation of the anti-inflammatory anti-hyperlipidaemic drug probucol (PB) would improve islet-graft survival and function, post transplantation in Type 1 diabetes (T1D). Methods. T1D was induced in mice, and biological profiles of the diabetic mice transplanted PB-microencapsulated islets harvested from healthy syngeneic mice were measured. Results and Conclusion. Compared with sham (no PB), the treated group showed significant reduction in serum levels of interleukin-1β, interleukin-6, interleukin-12, interleukin-17, and tumour necrosis factor-α, accompanied by a 3-fold increase in survival duration, which suggests PB islet-protective effects, post transplantation.

show abstract

Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies

Cited by 43 publications

References 156 publications

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study

Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study

Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid

Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions

Contact Info

Product

Resources

About